Reslizumab
Product Specifications
UNSPSC Description
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively[1][2].
Target Antigen
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/reslizumab.html
Purity
99.40
Solubility
H2O
Smiles
[Reslizumab]
References & Citations
[1]Liddament M, et al. Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. Allergy Asthma Immunol Res. 2019 Mar;11(2):291-298.|[2]Pérez de Llano LA, et al. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. Allergy. 2019 Sep 4.|[3]Egan RW, Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung. 1999 Sep;49(9):779-90.
Shipping Conditions
Blue Ice
Storage Conditions
Store at 4°C for 2 years, do not freeze
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P9949/Reslizumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P9949/Reslizumab-SDS-MedChemExpress.pdf
Clinical Information
Launched
CAS Number
241473-69-8
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
